— Aethlon Medical (NASDAQ: AEMD) reported third quarter 2020 net loss attributable to company of $820,000 or $0.28 per share vs. a loss of $2.1 million $1.67 per share in the prior-year quarter.
— Government contract revenue was $413,458 for the three months ended December 31, 2019.
— Operating expenses were $1.29 million compared to $1.96 million in the three months ended December 31, 2018.
— Aethlon announced that SEC had temporarily suspended trading of the company stock for a period of ten days.
— Aethlon clarified that its proprietary blood filtration cartridge Hemopurifier, which is in the development stage, would not be an initial front line treatment for the 2019-nCoV virus.
Most Popular
BK Earnings: Bank of New York Mellon Q3 2024 earnings climb on higher revenues
The Bank of New York Mellon Corporation (NYSE: BK) on Friday said its adjusted earnings increased in the third quarter of 2024. The financial service provider's assets under management and
BLK Earnings: BlackRock reports better-than-expected Q3 2024 results
Asset management company BlackRock, Inc. (NYSE: BLK) on Friday reported higher revenues and adjusted profit for the third quarter of 2024, which also came in above Wall Street's projections. Third-quarter
JPM Earnings: Key quarterly highlights from JPMorgan’s Q3 2024 financial results
JPMorgan Chase & Co. (NYSE: JPM) reported its third quarter 2024 earnings results today. Reported net revenue increased 7% year-over-year to $42.6 billion. Managed revenue rose 6% to $43.3 billion.
